• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·India·Healthcare·SEQUENT.NS
Share

Viyash Scientific Limited Stocks

₹ 216.33Last Updated 13.02.2026

Issuer Rating

3/7
Performance

Modest

Risk

Moderate

Recommendation

Sell

Market Cap

₹ 540.03M

₹ 216.33
Key Takeaways

Risk factor

Meaningful price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Viyash Scientific Limited is a global veterinary healthcare company with operations spanning Europe, Asia, and other international markets. It specializes in developing and supplying finished dosage forms for a range of therapeutic applications, including nutritional support, pain relief, parasite control, antibiotic treatments, and gut health solutions. These products cater to various animals like livestock, poultry, and domestic pets. Additionally, the company extends its expertise through analytical testing and specialized veterinary formulation services. Originally established as Sequent Scientific Limited, the company officially adopted the name Viyash Scientific Limited in January 2026. Founded in 1985, its corporate headquarters are situated in Hyderabad, India. Currently, Viyash Scientific Limited functions as a subsidiary of CA Harbor Investments.

Company Valuation

Overvalued
2/7

Based on key historical and expected multiples, the stock is overvalued relative to its peers. In particular, the stock is reasonably priced on P/E, 'expensive' on EV/EBI

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

12.06.2026 01:34

Rally ahead of SpaceX debut: best day since April for S&P 500 and Nasdaq, oil down 5%

12.06.2026 01:01

SpaceX holds record IPO: Elon Musk's space company raises $75 billion

12.06.2026 00:55

Google discusses producing part of its new AI chip at Samsung factories. Is this a threat to TSMC?

12.06.2026 00:10

BofA raised its rating on Intel stock by two notches at once. What is the bank betting on?

11.06.2026 22:46

Trump canceled planned new strikes on Iran. Oil below $90 per barrel

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn
  • X (Twitter)
  • LinkedIn
Oninvest© 2026